Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H53NO15 |
Molecular Weight | 811.8679 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CCC(=O)[C@H](C)O1)O[C@H]2[C@@H](O)C[C@]([H])(O[C@@H]3[C@H](C)O[C@]([H])(C[C@@H]3N(C)C)O[C@H]4C[C@](O)(CC)[C@H](C(=O)OC)C5=CC6=C(C(=O)C7=C(O)C=CC=C7C6=O)C(O)=C45)O[C@H]2C
InChI
InChIKey=USZYSDMBJDPRIF-SVEJIMAYSA-N
InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
Molecular Formula | C42H53NO15 |
Molecular Weight | 811.8679 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8
Curator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8
Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23533247 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3867405 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition by doxorubicin of human immuno-deficiency virus (HIV) infection and replication in vitro. | 1987 Mar |
|
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. | 1993 Dec |
|
Enhancement of chemosensitivity toward anticancer drugs by high expression of caspase-1 in NIH 3T3 cells. | 1998 Jan |
|
Oxidative stress involvement in chemically induced differentiation of K562 cells. | 2000 Jan 1 |
|
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. | 2000 May |
|
Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1. | 2003 Nov 28 |
|
Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. | 2005 Dec |
|
Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. | 2009 Mar 24 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Discovery, synthesis, and biological evaluation of novel SMN protein modulators. | 2011 Sep 22 |
Sample Use Guides
25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2912388
aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:48:08 UTC 2023
by
admin
on
Wed Jul 05 22:48:08 UTC 2023
|
Record UNII |
74KXF8I502
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL01DB04
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
||
|
WHO-ATC |
L01DB04
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
||
|
NCI_THESAURUS |
C987
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57576-44-0
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
451415
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
77980
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
CHEMBL502620
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
D015250
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
260-824-3
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
C202
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
100000084625
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
239
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | RxNorm | ||
|
80
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
74KXF8I502
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
4945
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
ACLARUBICIN
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
74619
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
SUB05243MIG
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
DTXSID1022554
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
M1374
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB11617
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY | |||
|
208734
Created by
admin on Wed Jul 05 22:48:08 UTC 2023 , Edited by admin on Wed Jul 05 22:48:08 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |